This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
24 May 2011

CT-011 Lymphoma Drug Shows Positive Phase II Results

The study showed that the drug increased the number of specific T-cells responsible for the maintenance of long-term immunologic memory.

Teva Pharmaceutical and CureTech have announced the positive Phase II results for CT-011, an investigational anti-PD-1 monoclonal antibody. The final Phase II results for CT-011 are expected to be available during Q3 of 2011.

 

The three-month study included patients with diffuse large B-cell lymphoma (DLBCL) and showed that the drug increased the number of specific T-cells responsible for the maintenance of long-term immunologic memory.

 

DLBCL is an aggressive type of non-Hodgkin's Lymphoma (NHL) affecting about 40% of all NHL patients. CT-011 blocks the PD-1 programmed death receptor and revitalises the body's own immune system.

 

The preliminary analysis al

Related News